HLA-E as an Emerging Checkpoint and Biomarker in Personalized Cancer Immunotherapy

Abstract

Human leukocyte antigen (HLA) molecules play a predominant role in cancer immunotherapy by harnessing the immune system’s capacity to differentiate between healthy and malignant cells. Most human cell types express HLA class I molecules, which interact with T-cell receptors (TCRs) to activate T cells and initiate adaptive immunological responses. The efficacy of several immunotherapeutic strategies, including checkpoint inhibitors, CAR-T-cell therapy, and personalized cancer vaccines, is significantly influenced by HLA diversity and polymorphisms. Human leukocyte antigen E (HLA-E) is a non-classical major histocompatibility complex class I (MHC-I) protein that plays a crucial role in immune regulation. Unlike classical HLA molecules, HLA-E exhibits unique immunosuppressive properties that influence tumor immune evasion mechanisms. Recent studies have highlighted the importance of HLA-E expression in various hematological malignancies and solid tumors. HLA-E interacts with inhibitory receptors on natural killer (NK) cells and certain T-cell subsets, thereby modulating immune responses against tumor cells. The expression of HLA-E on tumor cells can lead to immune escape by inhibiting the cytotoxic activity of NK and CD8+ T cells, which are critical for effective anti-tumor immunity. This review summarizes how HLA-E presents antigens, discusses recent advances in identifying HLA-E-restricted peptides, and evaluates current HLA-E-dependent and HLA-E-independent adoptive immunotherapies. Understanding the role of HLA-E in tumor immune evasion provides valuable insights for developing novel personalized cancer immunotherapies. Targeting HLA-E has the potential to increase the effectiveness of current treatments and improve patient prognosis across diverse cancer types.

Keywords

HLA-E / NKG2A / Cancer immunotherapy / Biomarkers / Immunocheckpoint inhibitors / Personalized medicine / Tumor immune evasion

References

[1] Szeto GL, Finley SD. Integrative approaches to cancer immunotherapy. Trends Cancer., 2019, 5(7): 400-410

[2] Riley RS, June CH, Langer R, et al.. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov., 2019, 18(3): 175-196

[3] Sung H, Ferlay J, Siegel RL, et al.. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin., 2021, 71(3): 209-249

[4] Wang Y, Wang M, Wu HX, et al.. Advancing to the era of cancer immunotherapy. Cancer Commun., 2021, 41(9): 803-829

[5] Bandara S, Raveendran S. Current landscape and future directions in cancer immunotherapy: therapies, trials, and challenges. Cancers., 2025, 17(5): 821

[6] Li H, Han S, Dong C, et al.. Advancements in conventional cancer therapy combined with immunotherapy. Oncol Transl Med., 2025, 11(1): 17-28

[7] Kim J, Maharjan R, Park J. Current trends and innovative approaches in cancer immunotherapy. AAPS PharmSciTech., 2024, 25(6): 168

[8] Tang L, Huang Z, Mei H, et al.. Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. Signal Transduct Target Ther., 2023, 8(1): 306

[9] Liu B, Zhou H, Tan L, et al.. Exploring treatment options in cancer: tumor treatment strategies. Signal Transduct Target Ther., 2024, 9: 175

[10] Kiyotani K, Toyoshima Y, Nakamura Y. Personalized immunotherapy in cancer precision medicine. Cancer Biol Med., 2021, 18(4): 955-965

[11] Sankar K, Ye JC, Li Z, et al.. The role of biomarkers in personalized immunotherapy. Biomark Res., 2022, 10(1): 32

[12] Holtsträter C, Schrörs B, Bukur T, et al. Bioinformatics for cancer immunotherapy. Bioinformatics for Cancer Immunotherapy. New York, NY: Springer US,; 2020:1–9.

[13] Jain KK. Personalized immuno-oncology. Textbook of Personalized Medicine. Cham: Springer International Publishing,; 2020:479–508.

[14] Dyikanov D, Zaitsev A, Vasileva T, et al.. Comprehensive peripheral blood immunoprofiling reveals five immunotypes with immunotherapy response characteristics in patients with cancer. Cancer Cell., 2024, 42(5): 759-779.e12

[15] Botticelli A, Pomati G, Cirillo A, et al.. The role of immune profile in predicting outcomes in cancer patients treated with immunotherapy. Front Immunol., 2022, 13 Article ID: 974087

[16] Schaafsma E, Fugle CM, Wang X, et al.. Pan-cancer association of HLA gene expression with cancer prognosis and immunotherapy efficacy. Br J Cancer., 2021, 125(3): 422-432

[17] Jhunjhunwala S, Hammer C, Delamarre L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nat Rev Cancer., 2021, 21(5): 298-312

[18] Pishesha N, Harmand TJ, Ploegh HL. A guide to antigen processing and presentation. Nat Rev Immunol., 2022, 22(12): 751-764

[19] Bukur J, Jasinski S, Seliger B. The role of classical and non-classical HLA class I antigens in human tumors. Semin Cancer Biol., 2012, 22(4): 350-358

[20] Benitez Fuentes JD, Bartolome Arcilla J, Mohamed Mohamed K, et al.. Targeting of non-classical human leukocyte antigens as novel therapeutic strategies in cancer. Cancers., 2024, 16(24): 4266

[21] Gillespie GM, Quastel MN, McMichael AJ. HLA-E: immune receptor functional mechanisms revealed by structural studies. Immunol Rev., 2025, 329(1): Article ID: e13434

[22] Bartolome J, Molto C, Benitez-Fuentes JD, et al.. Prognostic value of human leukocyte antigen G expression in solid tumors: a systematic review and meta-analysis. Front Immunol., 2023, 14: 1165813

[23] Benitez Fuentes JD, Bartolome Arcilla J, Lazaro Sanchez AD, et al.. Association between human leukocyte antigen E expression and outcomes in solid tumors: a systematic review and meta-analysis. Front Oncol., 2025, 15: 1525924

[24] Kyrysyuk O, Wucherpfennig KW. Designing cancer immunotherapies that engage T cells and NK cells. Annu Rev Immunol., 2023, 41: 17-38

[25] Kulski JK, Suzuki S, Shiina T. Human leukocyte antigen super-locus: nexus of genomic supergenes, SNPs, indels, transcripts, and haplotypes. Hum Genome Var., 2022, 9(1): 49

[26] Kraemer T, Blasczyk R, Bade-Doeding C. HLA-E: a novel player for histocompatibility. J Immunol Res., 2014, 2014(1): Article ID: 352160

[27] Celik AA, Kraemer T, Huyton T, et al.. The diversity of the HLA-E-restricted peptide repertoire explains the immunological impact of the Arg107Gly mismatch. Immunogenetics., 2016, 68(1): 29-41

[28] Kanevskiy L, Erokhina S, Kobyzeva P, et al.. Dimorphism of HLA-E and its disease association. Int J Mol Sci., 2019, 20(21): 5496

[29] Grimsley C, Ober C. Population genetic studies of HLA-E: evidence for selection. Hum Immunol., 1997, 52(1): 33-40

[30] Weitzen M, Shahbazy M, Kapoor S, et al.. Deciphering the HLA-E immunopeptidome with mass spectrometry: an opportunity for universal mRNA vaccines and T-cell-directed immunotherapies. Front Immunol., 2024, 15: 1442783

[31] Walters LC, Rozbesky D, Harlos K, et al.. Primary and secondary functions of HLA-E are determined by stability and conformation of the peptide-bound complexes. Cell Rep., 2022, 39(11): Article ID: 110959

[32] Lee N, Llano M, Carretero M, et al.. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci U S A., 1998, 95(9): 5199-5204

[33] O’Callaghan CA, Tormo J, Willcox BE, et al.. Structural features impose tight peptide binding specificity in the nonclassical MHC molecule HLA-E. Mol Cell., 1998, 1(4): 531-541

[34] Braud VM, Allan DSJ, O’Callaghan CA, et al.. HLA-E binds to natural killer cell receptors CD94/NKG2A. B and C. Nature., 1998, 391(6669): 795-799

[35] Borrego F, Ulbrecht M, Weiss EH, et al.. Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence–derived peptides by CD94/NKG2 confers protection from natural killer cell–mediated lysis. J Exp Med., 1998, 187(5): 813-818

[36] He W, Gea-Mallorquí E, Colin-York H, et al.. Intracellular trafficking of HLA-E and its regulation. J Exp Med., 2023, 220(8): Article ID: e20221941

[37] Borst L, van der Burg SH, van Hall T. The NKG2A–HLA-E axis as a novel checkpoint in the tumor microenvironment. Clin Cancer Res., 2020, 26(21): 5549-5556

[38] Valés-Gómez M, Reyburn HT, Erskine RA, et al.. Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94/NKG2-A and the activating receptor CD94/NKG2-C to HLA-E. EMBO J., 1999, 18(15): 4250-4260

[39] Pérez-Villar JJ, Melero I, Navarro F, et al.. The CD94/NKG2-a inhibitory receptor complex is involved in natural killer cell-mediated recognition of cells expressing HLA-G1. J Immunol., 1997, 158(12): 5736-5743

[40] Llano M, Lee N, Navarro F, et al.. HLA-E-bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors: preferential response to an HLA-G-derived nonamer. Eur J Immunol., 1998, 28(9): 2854-2863

[41] Wagner B, da Silva Nardi F, Schramm S, et al.. HLA-E allelic genotype correlates with HLA-E plasma levels and predicts early progression in chronic lymphocytic leukemia. Cancer., 2017, 123(5): 814-823

[42] Zheng H, Lu R, Xie S, et al.. Human leukocyte antigen-E alleles and expression in patients with serous ovarian cancer. Cancer Sci., 2015, 106(5): 522-528

[43] Xu YP, Wieten L, Wang SX, et al.. Clinical significance of HLA-E genotype and surface/soluble expression levels between healthy individuals and patients with acute leukemia. Leuk Lymphoma., 2019, 60(1): 208-215

[44] Hirankarn N, Kimkong I, Mutirangura A. HLA-E polymorphism in patients with nasopharyngeal carcinoma. Tissue Antigens., 2004, 64(5): 588-592

[45] Douik H, Romdhane NA, Guemira F. Are HLA-E*0103 alleles predictive markers for nasopharyngeal cancer risk?. Pathol Res Pract., 2016, 212(4): 345-349

[46] Martín P, Krsnik I, Navarro B, et al.. HLA allele E*01: 01 is associated with a reduced risk of EBV-related classical Hodgkin lymphoma independently of HLA-A*01/*02. PLoS One., 2015, 10(8): Article ID: e0135512

[47] King A, Allan DS, Bowen M, et al.. HLA-E is expressed on trophoblast and interacts with CD94/NKG2 receptors on decidual NK cells. Eur J Immunol., 2000, 30(6): 1623-1631

[48] Kaiser BK, Barahmand-Pour F, Paulsene W, et al.. Interactions between NKG2x immunoreceptors and HLA-E ligands display overlapping affinities and thermodynamics. J Immunol., 2005, 174(5): 2878-2884

[49] Liu X, Song J, Zhang H, et al.. Immune checkpoint HLA-E: CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance. Cancer Cell., 2023, 41(2): 272-287.e9

[50] Photos C. HLA-E:CD94–NKG2A Mediates Circulating Tumor Cell Immune Evasion. Cancer Discov, 2023, 13: 806-806

[51] Middelburg J, Ghaffari S, Schoufour TAW, et al.. The MHC-E peptide ligands for checkpoint CD94/NKG2A are governed by inflammatory signals, whereas LILRB1/2 receptors are peptide indifferent. Cell Rep., 2023, 42(12): Article ID: 113516

[52] Mac Donald A, Guipouy D, Lemieux W, et al.. KLRC1 knockout overcomes HLA-E-mediated inhibition and improves NK cell antitumor activity against solid tumors. Front Immunol., 2023, 14: 1231916

[53] Lagana A, Ruan DF, Melnekoff D, et al.. Increased HLA-E expression correlates with early relapse in multiple myeloma. Blood., 2018, 132: 59

[54] Abd Hamid M, Wang RZ, Yao X, et al.. Enriched HLA-E and CD94/NKG2A interaction limits antitumor CD8⁺ tumor-infiltrating T lymphocyte responses. Cancer Immunol Res., 2019, 7(8): 1293-1306

[55] Fisher JG, Doyle ADP, Graham LV, et al.. XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression. Leukemia., 2023, 37(10): 2036-2049

[56] Ismael A, Robinette AJ, Huric L, et al.. CREB1 promotes expression of immune checkpoint HLA-E leading to immune escape in multiple myeloma. Leukemia., 2024, 38(8): 1777-1786

[57] Kamiya T, Seow SV, Wong D, et al.. Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells. J Clin Invest., 2019, 129(5): 2094-2106

[58] Liu B, Zhou H, Tan L, et al.. Exploring treatment options in cancer: Tumor treatment strategies. Signal Transduct Target Ther., 2024, 9(1): 175

[59] Courau T, Bonnereau J, Chicoteau J, et al.. Cocultures of human colorectal tumor spheroids with immune cells reveal the therapeutic potential of MICA/B and NKG2A targeting for cancer treatment. J Immunother Cancer., 2019, 7(1): 74

[60] Myers JA, Schirm D, Bendzick L, et al.. Balanced engagement of activating and inhibitory receptors mitigates human NK cell exhaustion. JCI Insight., 2022, 7(15): Article ID: e150079

[61] Cheng W, Zhu N, Wang J, et al.. A role of gut microbiota metabolites in HLA-E and NKG2 blockage immunotherapy against tumors: new insights for clinical application. Front Immunol., 2024, 15: 1331518

[62] Li Y, Li Z, Tang Y, et al.. Unlocking the therapeutic potential of the NKG2A-HLA-E immune checkpoint pathway in T cells and NK cells for cancer immunotherapy. J Immunother Cancer., 2024, 12(10): Article ID: e009934

[63] Liang YH, Chen KH, Tsai JH, et al.. Proteasome inhibitors restore the STAT1 pathway and enhance the expression of MHC class I on human colon cancer cells. J Biomed Sci., 2021, 28(1): 75

[64] Derré L, Corvaisier M, Charreau B, et al.. Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells. J Immunol., 2006, 177(5): 3100-3107

[65] Coupel S, Moreau A, Hamidou M, et al.. Expression and release of soluble HLA-E is an immunoregulatory feature of endothelial cell activation. Blood., 2007, 109(7): 2806-2814

[66] Pereira BI, Devine OP, Vukmanovic-Stejic M, et al.. Senescent cells evade immune clearance via HLA-E-mediated NK and CD8⁺ T cell inhibition. Nat Commun., 2019, 10(1): 2387

[67] Sheehy MJ, Meske LM, Emler CA, et al.. Allelic T-cell receptor alpha complexes have little or no influence on susceptibility to type 1 diabetes. Hum Immunol., 1989, 26(4): 261-271

[68] Lin Z, Bashirova AA, Viard M, et al.. HLA class I signal peptide polymorphism determines the level of CD94/NKG2-HLA-E-mediated regulation of effector cell responses. Nat Immunol., 2023, 24(7): 1087-1097

[69] Jiang H, Yu D, Yang P, et al.. Revealing the transcriptional heterogeneity of organ-specific metastasis in human gastric cancer using single-cell RNA Sequencing. Clin Transl Med., 2022, 12(2): Article ID: e730

[70] Sasaki T, Kanaseki T, Shionoya Y, et al.. Microenvironmental stresses induce HLA-E/Qa-1 surface expression and thereby reduce CD8⁺ T-cell recognition of stressed cells. Eur J Immunol., 2016, 46(4): 929-940

[71] Hrbac T, Kopkova A, Siegl F, et al.. HLA-E and HLA-F are overexpressed in glioblastoma and HLA-E increased after exposure to ionizing radiation. Cancer Genomics Proteomics., 2022, 19(2): 151-162

[72] Yang Y, Liu Z, Wang H, et al.. HLA-E binding peptide as a potential therapeutic candidate for high-risk multiple myeloma. Front Oncol., 2021, 11 Article ID: 670673

[73] Boujelbene N, Ben Yahia H, Babay W, et al.. HLA-G, HLA-E, and IDO overexpression predicts a worse survival of Tunisian patients with vulvar squamous cell carcinoma. HLA., 2019, 94(1): 11-24

[74] Morinaga T, Iwatsuki M, Yamashita K, et al.. Evaluation of HLA-E expression combined with natural killer cell status as a prognostic factor for advanced gastric cancer. Ann Surg Oncol., 2022, 29(8): 4951-4960

[75] Benevolo M, Mottolese M, Tremante E, et al.. High expression of HLA-E in colorectal carcinoma is associated with a favorable prognosis. J Transl Med., 2011, 9: 184

[76] Seliger B, Jasinski-Bergner S, Quandt D, et al.. HLA-E expression and its clinical relevance in human renal cell carcinoma. Oncotarget., 2016, 7(41): 67360-67372

[77] Zhen ZJ, Ling JY, Cai Y, et al.. Impact of HLA-E gene polymorphism on HLA-E expression in tumor cells and prognosis in patients with stage III colorectal cancer. Med Oncol., 2013, 30(1): 482

[78] Feng X, Lai X, Zhou M, et al.. Targeting HLA-E in lung cancer: the therapeutic potential of IRF5-engineered M1-macrophage-derived exosomes. Clin Respir J., 2024, 18(12): Article ID: e70035

[79] Lauterbach N, Wieten L, Popeijus HE, et al.. HLA-E regulates NKG2C+ natural killer cell function through presentation of a restricted peptide repertoire. Hum Immunol., 2015, 76(8): 578-586

[80] Battin C, Kaufmann G, Leitner J, et al.. NKG2A-checkpoint inhibition and its blockade critically depends on peptides presented by its ligand HLA-E. Immunology., 2022, 166(4): 507-521

[81] Matsunami K, Nakai MS, et al.. Modulation of the leader peptide sequence of the HLA-E gene up-regulates its expression and down-regulates natural killer cell-mediated swine endothelial cell lysis. Transplantation., 2002, 73(10): 1582-1589

[82] Chiossone L, Dumas PY, Vienne M, et al.. Natural killer cells and other innate lymphoid cells in cancer. Nat Rev Immunol., 2018, 18(11): 671-688

[83] Capuano C, Pighi C, Battella S, et al.. Harnessing CD16-mediated NK cell functions to enhance therapeutic efficacy of tumor-targeting mAbs. Cancers., 2021, 13(10): 2500

[84] André P, Denis C, Soulas C, et al.. Anti-NKG2A MAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell., 2018, 175(7): 1731-1743.e13

[85] Lee J, Keam B, Park HR, et al.. Monalizumab efficacy correlates with HLA-E surface expression and NK cell activity in head and neck squamous carcinoma cell lines. J Cancer Res Clin Oncol., 2023, 149(9): 5705-5715

[86] Gelman JS, Sironi J, Berezniuk I, et al.. Alterations of the intracellular peptidome in response to the proteasome inhibitor bortezomib. PLoS One., 2013, 8(1): Article ID: e53263

[87] Thangaraj JL, Ahn SY, Jung SH, et al.. Expanded natural killer cells augment the antimyeloma effect of daratumumab, bortezomib, and dexamethasone in a mouse model. Cell Mol Immunol., 2021, 18(7): 1652-1661

[88] Yun HD, Schirm DK, Felices M, et al.. Dinaciclib enhances natural killer cell cytotoxicity against acute myelogenous leukemia. Blood Adv., 2019, 3(16): 2448-2452

[89] Zhang M, Zhang L, Hei R, et al.. CDK inhibitors in cancer therapy, an overview of recent development. Am J Cancer Res., 2021, 11(5): 1913-1935

[90] Ruscetti M, Leibold J, Bott MJ, et al.. NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. Science., 2018, 362(6421): 1416-1422

[91] Fisher JG, Walker CJ, Doyle AD, et al.. Selinexor enhances NK cell activation against malignant B cells via downregulation of HLA-E. Front Oncol., 2021, 11 Article ID: 785635

[92] Sheffer M, Lowry E, Beelen N, et al.. Genome-scale screens identify factors regulating tumor cell responses to natural killer cells. Nat Genet., 2021, 53(8): 1196-1206

[93] Hu X, Li J, Fu M, et al.. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther., 2021, 6(1): 402

[94] Berenson JR, Martinez D, Safaie T, et al.. Ruxolitinib and methylprednisolone for treatment of patients with relapsed/refractory multiple myeloma. Br J Haematol., 2023, 200(6): 722-730

[95] Michelin S, Gallegos CE, Dubner D, et al.. Ionizing radiation modulates the surface expression of human leukocyte antigen-G in a human melanoma cell line. Hum Immunol., 2009, 70(12): 1010-1015

[96] Battaglia NG, Murphy JD, Uccello TP, et al.. Combination of NKG2A and PD-1 blockade improves radiotherapy response in radioresistant tumors. J Immunol., 2022, 209(3): 629-640

[97] Tuomela K, Mukherjee D, Ambrose AR, et al.. Radiotherapy transiently reduces the sensitivity of cancer cells to lymphocyte cytotoxicity. Proc Natl Acad Sci U S A., 2022, 119(3): Article ID: e2111900119

[98] Pagliuca S, Gurnari C, Rubio MT, et al.. Individual HLA heterogeneity and its implications for cellular immune evasion in cancer and beyond. Front Immunol., 2022, 13 Article ID: 944872

[99] Liu X, Zuo F, Song J, et al.. Immune checkpoints HLA-E: CD94-NKG2A and HLA-C: KIR2DL1 complementarily shield circulating tumor cells from NK-mediated immune surveillance. Cell Discov., 2024, 10(1): 16

[100] Salomé B, Sfakianos JP, Ranti D, et al.. NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer. Cancer Cell., 2022, 40(9): 1027-1043.e9

[101] Bexte T, Albinger N, Al Ajami A, et al.. CRISPR/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells. Nat Commun., 2024, 15(1): 8439

[102] Gurung HR, Heidersbach AJ, Darwish M, et al.. Systematic discovery of neoepitope-HLA pairs for neoantigens shared among patients and tumor types. Nat Biotechnol., 2024, 42(7): 1107-1117

[103] Wohlwend J, Nathan A, Shalon N, et al.. Deep learning enhances the prediction of HLA class I-presented CD8⁺ T cell epitopes in foreign pathogens. Nat Mach Intell., 2025, 7(2): 232-243

[104] Altvater B, Kailayangiri S, Pérez Lanuza LF, et al.. HLA-G and HLA-E immune checkpoints are widely expressed in ewing sarcoma but have limited functional impact on the effector functions of antigen-specific CAR T cells. Cancers., 2021, 13(12): 2857

[105] Iyer RF, Verweij MC, Nair SS, et al.. CD8⁺T cell targeting of tumor antigens presented by HLA-E. Sci Adv, 2024, 10(19): eadm7515

[106] Zheng H, Guan X, Meng X, et al.. IFN-γ in ovarian tumor microenvironment upregulates HLA-E expression and predicts a poor prognosis. J Ovarian Res., 2023, 16(1): 229

[107] Radermacher A, Fehrenz M, Bellin T, et al.. HLA-E and its soluble form as indicators of a sex-specific immune response in patients with oral squamous cell carcinoma. Int J Mol Sci., 2023, 24(23): 16699

[108] Cascone T, Kar G, Spicer JD, et al.. Neoadjuvant durvalumab alone or combined with novel immuno-oncology agents in resectable lung cancer: the phase II NeoCOAST platform trial. Cancer Discov., 2023, 13(11): 2394-2411

[109] Herbst RS, Majem M, Barlesi F, et al.. COAST: an open-label, phase II, multidrug platform study of durvalumab alone or in combination with oleclumab or monalizumab in patients with unresectable, stage III non-small-cell lung cancer. J Clin Oncol., 2022, 40(29): 3383-3393

[110] Patel SP, Alonso-Gordoa T, Banerjee S, et al.. Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors. J Immunother Cancer., 2024, 12(2): Article ID: e007340

[111] Fisher JG, Graham LV, Blunt MD. Strategies to disrupt NKG2A: HLA-E interactions for improved anti-cancer immunity. Oncotarget., 2024, 15: 501-503

[112] Fisher JG, Doyle ADP, Graham LV, et al.. Disruption of the NKG2A: HLA-E immune checkpoint axis to enhance NK cell activation against cancer. Vaccines., 2022, 10(12): 1993

Funding

Universiti Sains Malaysia(R502-KR-ARU004-0000001081-K134)

RIGHTS & PERMISSIONS

The Author(s), under exclusive licence to the Huazhong University of Science and Technology